Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × lenvatinib × Gynecologic × Clear all

Phase

Status

Sponsor Class

OTHER 13 INDUSTRY 13 OTHER_GOV 1 NIH 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Gynecologic 1 Gastrointestinal 1

Conditions

Endometrial Neoplasms 1

Interventions

Cisplatin 55 Paclitaxel 47 Carboplatin 32 Radiotherapy 20 Taxes 19 Brachytherapy 15 Gemcitabine 13 Platinum 12 Doxorubicin 12 1,2-diaminocyclohexaneplatinum II citrate 12 Topotecan 9 Filgrastim 9 Docetaxel 8 Radiation 7 Chemotherapy, Adjuvant 7 Surgical Procedures, Operative 6 Polymerase Chain Reaction 6 Ifosfamide 6 Watchful Waiting 5 Radiotherapy, Intensity-Modulated 5 Granulocyte Colony-Stimulating Factor 5 Gene Expression Profiling 5 Fluorouracil 5 Etoposide 5 pegfilgrastim 4 Radiotherapy, Conformal 4 Observation 4 Amifostine 4 paclitaxel poliglumex 3 Pemetrexed 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03005015 2016-12-29

Lenvatinib in Second Line Endometrial Carcinoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡